|
|
|
|
| LEADER |
02882nam a2200301 u 4500 |
| 001 |
EB002001166 |
| 003 |
EBX01000000000000001164067 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Donahue, Katrina E.
|
| 245 |
0 |
0 |
|a Comparative effectiveness of drug therapy for rheumatoid arthritis, and psoriatic arthritis in adults
|h Elektronische Ressource
|c prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by RTI-University of North Carolina Evidence-based Practice Center ; investigators, Katrina E. Donahue ... [et al.]
|
| 260 |
|
|
|a [Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2007, 2007]
|
| 300 |
|
|
|a 1 PDF file (1 v. (various pagings)
|b ill
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Antirheumatic Agents / therapeutic use
|
| 653 |
|
|
|a Arthritis, Rheumatoid / drug therapy
|
| 653 |
|
|
|a Arthritis, Psoriatic / drug therapy
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a RTI International-University of North Carolina Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Comparative effectiveness review
|
| 500 |
|
|
|a Title from PDF t.p. (viewed Aug. 30, 2011). - "November 2007.". - "Contract no. 290-02-0016."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK43126
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a This report from the RTI-University of North Carolina Evidence-based Practice Center summarizes the evidence on the comparative efficacy, effectiveness, and harms of corticosteroids, synthetic DMARDs, and biologic DMARDs in the treatment of patients with either rheumatoid arthritis (RA) or psoriatic arthritis (PsA). The key questions (KQs) were developed through a public process in conjunction with the Scientific Resource Center at the Oregon Health and Science University. The KQs are as follows: KQ 1. For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in their ability to reduce patient-reported symptoms, to slow or limit progression of radiographic joint damage, or to maintain remission? KQ 2. For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in their ability to improve functional capacity or quality of life? KQ 3. For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in harms, tolerability, adherence, or adverse effects? KQ 4. What are the comparative benefits and harms of drug therapies for rheumatoid arthritis and psoriatic arthritis in subgroups of patients based on stage of disease, history of prior therapy, demographics, concomitant therapies, or comorbidities?
|